ARS Pharmaceuticals to Showcase Innovations at Key Conferences
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a dedicated biopharmaceutical company, focuses on empowering at-risk patients and their caregivers. The firm aims to enhance protection against severe allergic reactions that might lead to anaphylaxis. In an exciting announcement, prominent leaders Richard Lowenthal, Co-Founder, President and CEO, alongside Eric Karas, Chief Commercial Officer, will represent the company at two important events in June.
Details of Upcoming Conferences
ARS Pharmaceuticals is set to present at the following significant conferences this June:
William Blair 45th Annual Growth Stock Conference
The firm will present on Tuesday, June 3, at 11:20 a.m. CT in Chicago. Attendees will have the opportunity to witness the presentation through a live webcast, which can be accessed via their official investor portal.
2025 Jefferies Global Healthcare Conference
Mark your calendars for Wednesday, June 4, when ARS Pharmaceuticals will showcase their expertise at 5:30 p.m. ET in New York City. A live webcast will also be available for those interested in tuning in.
Engagement with Investors
In addition to the scheduled presentations, ARS Pharmaceuticals management looks forward to engaging in one-on-one meetings with potential investors during the Scotiabank Third Annual Healthcare Canadian Investor Day on June 17 in Toronto. This event provides a platform for personalized discussions and networking opportunities.
About ARS Pharmaceuticals
ARS Pharmaceuticals strives to empower patients vulnerable to allergic reactions. Their standout product, neffy, an epinephrine nasal spray, is designed for quick emergency treatment of anaphylaxis. It serves adult patients and children aged four and older who meet the weight requirements. Beyond the U.S. market, neffy (branded as EURneffy in the EU) addresses a variety of allergens, including those caused by food and insect stings.
Contact ARS Pharmaceuticals
Investor Contact:
Justin Chakma, ARS Pharma
Email: justinc@ars-pharma.com
Media Contact:
Christy Curran, Sam Brown Inc.
Email: christycurran@sambrown.com
Phone: 615.414.8668
Frequently Asked Questions
What is ARS Pharmaceuticals known for?
ARS Pharmaceuticals specializes in providing solutions for patients at risk of severe allergic reactions, notably with their product, neffy.
What conferences will ARS Pharmaceuticals participate in?
They will present at the William Blair Annual Growth Stock Conference and the Jefferies Global Healthcare Conference this June.
What is the purpose of the presentations?
The presentations aim to share the company’s innovations and potential for empowering patients against allergic reactions.
Where can I watch the presentations?
The presentations will be available via live webcasts, accessible through the company's investor portal.
How can I contact ARS Pharmaceuticals?
For inquiries, you can reach out to Justin Chakma at justinc@ars-pharma.com or Christy Curran at christycurran@sambrown.com.